N/A N=230 Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)
HIV
Primary: HIV Testing Frequency — 5.3; 3.6 HIV tests — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=258 A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
Breast Cancer
Primary: Progression-Free Survival (PFS) — 18.89; 15.80; 20.63; 15.80 months — p=0.0070
Phase 2 N=121 IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Retinopathy of Prematurity (ROP)
Primary: Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population — 14; 24; 4; 4 participants — p=0.0642
N/A N=10 Symphion® System In-Office Study
Uterine Leiomyomas · Endometrial Polyps
Primary: Safety Profile of the Symphion® Bipolar Hysteroscopic Tissue Resection System When Used in the Office Setting for the Removal of Intracavitary Polyps and Myomas. — 0; 0…
Phase 2 N=187 Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Typhoid
Primary: Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions. — 0; 0; 0; 0 Participants
Phase 2 N=112 The Effect of Yohimbine on Cocaine Cue Reactivity
Cocaine Related Disorders
Primary: Cocaine Craving — 4.8; 3.4; 3.0; 2.7 units on a scale
N/A N=20 Intraosseous Pressure Monitoring in Intensive Care Unit Patients
Blood Pressure
Primary: Standardized Ratio as a Percentage Between Mean IOP and Mean Arterial Pressure — 34.5; 40.5; 40.1 percentage of IO pressure to cuff pressu
Phase 2 N=60 Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Graft vs Host Disease
Primary: Cummalative Incidence of Grade 2 to 4 Acute Graft vs Host Diesease (GVHD) at Day 100 Post Transplant in HSCT Recipients — 3.3 percentage of participants — p=<0.05
Phase 4 N=60 Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain
Typical Facial Pain · Atypical Facial Pain
Primary: The Proportion of Subjects Reporting at Least 50% Overall Pain Relief — 19; 14; 10; 16 Participants — p=.196
N/A N=19 Effects of Intravenous Lidocaine on Endometriosis Pain
Endometriosis
Primary: Change in Visual Analogue Scale (VAS) — -2.6; -0.2; -3.5; -1.5 units on a scale
Phase 2 N=13 Role of Leptin in the Neuroendocrine and Immune Response to Fasting
Fasting
Primary: Cortisol — 17.5; 16.9 ug/dl
Phase 2 N=13 Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults
Sleep Apnea, Obstructive
Primary: Genioglossus Activity During Sleep Expressed as %Wakefulness Value (Before Drug/Placebo Administration). — 166; 136; 245; 163 percentage of wakefulness value — p=0.85
Phase 3 N=40 Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia
Primary Thrombocytopenia
Primary: Percentage of Responders — 80.6 Percentage of participants
Phase 4 N=221 A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
Parapsoriasis
Primary: Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16 — -10.17; -48.07…
N/A N=89 Infrared Lymphangiography as a Method of Sentinel Node Identification
Melanoma · Sentinel Node
Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient